Overview

Trial in Low Grade Glioma Patients: Wait or Treat

Status:
Recruiting
Trial end date:
2031-10-01
Target enrollment:
Participant gender:
Summary
The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment. It will establish whether early adjuvant treatment with radiotherapy and adjuvant temozolomide in resected IDHmutated astrocytoma will improve outcome, and whether benefits of early treatment outweigh potential side-effects of that, such as deterioration in neurocognitive function or Quality of Live, seizure activity and Patient Reported outcome compared to active surveillance.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborator:
Cooperative Trials Group for Neuro-Oncology (COGNO)
Treatments:
Temozolomide